痴呆症预防和治疗:叙述性审查
David B Reuben1, Sarah Kremen2,3, Donovan T Maust4,5
1Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine, University of California, Los Angeles.
JAMA internal medicine
|March 4, 2024
概括
预防痴呆症仍然具有挑战性,因为没有任何干预措施可以最终预防它. 然而,管理风险因素提供了其他健康益处,目前的治疗方法对阿尔茨海默病和其他痴呆症提供了适度的改善.
科学领域:
- 老年病学和神经病学
- 公共卫生 公共卫生
背景情况:
- 痴呆症的患病率随着年龄的增长而显著增加,影响认知,行为和功能能力.
- 人口老龄化需要有效的痴呆症预防和治疗策略.
研究的目的:
- 审查目前对痴呆症预防和治疗的理解和方法.
- 为了突出解决可修改的风险因素的重要性,尽管有限的最终预防数据.
主要方法:
- 审查有关痴呆症风险因素,预防策略和治疗选择的现有文献.
- 对各种痴呆症类型的当前药理和非药理干预措施的分析.
主要成果:
- 没有随机临床试验证实干预措施可以预防痴呆症,但解决风险因素是有益的.
- 胆酶抑制剂,美曼丁和抗粉样蛋白免疫调节剂对阿尔茨海默病和其他痴呆症提供了适度的益处.
- 对于行为症状,非药物治疗方法是首选的;精神药物药物的有效性和风险有限.
结论:
- 目前的痴呆症预防和治疗策略并没有取得最佳的成功.
- 持续的研究和投资对于开发未来解决方案来减少全球痴呆症负担至关重要.
相关概念视频
Alzheimer's Disease: Treatment
188
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
188
Dementia
113
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
113
Alzheimer's Disease: Overview
481
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
481
Parkinson's Disease: Treatment
268
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
268
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
125
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
125
Parkinson's Disease: Overview
544
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
544


